Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.

A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia.

Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal S, Herben V, Kusumakar V, Yuen E, Palumbo J.

J Clin Psychopharmacol. 2010 Jun;30(3):235-44. doi: 10.1097/JCP.0b013e3181dd3103. Erratum in: J Clin Psychopharmacol. 2010 Aug;30(4):364.

PMID:
20473057
2.

Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study.

Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, Eerdekens MH, Brown DW.

Int Clin Psychopharmacol. 2010 Sep;25(5):247-56. doi: 10.1097/YIC.0b013e32833948fa.

PMID:
20389255
3.
4.

Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia.

Hough D, Lindenmayer JP, Gopal S, Melkote R, Lim P, Herben V, Yuen E, Eerdekens M.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Aug 31;33(6):1022-31. doi: 10.1016/j.pnpbp.2009.05.014. Epub 2009 May 28.

PMID:
19481579
5.

A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.

Li H, Rui Q, Ning X, Xu H, Gu N.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):1002-8. doi: 10.1016/j.pnpbp.2011.02.001. Epub 2011 Feb 18.

PMID:
21315787
6.

A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.

Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D.

J Psychopharmacol. 2011 May;25(5):685-97. doi: 10.1177/0269881110372817. Epub 2010 Jul 8.

PMID:
20615933
7.

Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia.

Gopal S, Gassmann-Mayer C, Palumbo J, Samtani MN, Shiwach R, Alphs L.

Curr Med Res Opin. 2010 Feb;26(2):377-87. doi: 10.1185/03007990903482772. Review.

PMID:
20001492
8.

Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study.

Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, Eerdekens M.

Int J Neuropsychopharmacol. 2010 Jun;13(5):635-47. doi: 10.1017/S1461145709990988. Epub 2009 Nov 27.

PMID:
19941696
9.

Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.

Berwaerts J, Liu Y, Gopal S, Nuamah I, Xu H, Savitz A, Coppola D, Schotte A, Remmerie B, Maruta N, Hough DW.

JAMA Psychiatry. 2015 Aug;72(8):830-9. doi: 10.1001/jamapsychiatry.2015.0241.

PMID:
25820612
10.

A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia.

Pandina G, Lane R, Gopal S, Gassmann-Mayer C, Hough D, Remmerie B, Simpson G.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15;35(1):218-26. doi: 10.1016/j.pnpbp.2010.11.008. Epub 2010 Nov 16.

PMID:
21092748
11.

A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia.

Nasrallah HA, Gopal S, Gassmann-Mayer C, Quiroz JA, Lim P, Eerdekens M, Yuen E, Hough D.

Neuropsychopharmacology. 2010 Sep;35(10):2072-82. doi: 10.1038/npp.2010.79. Epub 2010 Jun 16.

12.

Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.

Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, Eerdekens M.

J Clin Psychiatry. 2008 May;69(5):817-29.

PMID:
18466043
13.

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M.

Schizophr Res. 2010 Feb;116(2-3):107-17. doi: 10.1016/j.schres.2009.10.026. Epub 2009 Dec 2.

PMID:
19959339
14.

Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.

Fu DJ, Bossie CA, Kern Sliwa J, Ma YW, Alphs L.

Clin Schizophr Relat Psychoses. 2014 Jul;8(2):101-9, 109A. doi: 10.3371/CSRP.FUBO.022213.

PMID:
23446197
15.
16.

A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.

Coppola D, Liu Y, Gopal S, Remmerie B, Samtani MN, Hough DW, Nuamah I, Sulaiman A, Pandina G.

BMC Psychiatry. 2012 Mar 28;12:26. doi: 10.1186/1471-244X-12-26.

17.

Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.

Tzimos A, Samokhvalov V, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M.

Am J Geriatr Psychiatry. 2008 Jan;16(1):31-43. doi: 10.1097/JGP.0b013e31815a3e7a.

PMID:
18165460
18.

A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia.

Fleischhacker WW, Gopal S, Lane R, Gassmann-Mayer C, Lim P, Hough D, Remmerie B, Eerdekens M.

Int J Neuropsychopharmacol. 2012 Feb;15(1):107-18. doi: 10.1017/S1461145711001076. Epub 2011 Jul 22. Erratum in: Int J Neuropsychopharmacol. 2012 Feb;15(1):119. Dosage error in article text.

PMID:
21777507
19.

Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study.

Alphs L, Benson C, Cheshire-Kinney K, Lindenmayer JP, Mao L, Rodriguez SC, Starr HL.

J Clin Psychiatry. 2015 May;76(5):554-61. doi: 10.4088/JCP.14m09584.

20.

A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents.

Singh J, Robb A, Vijapurkar U, Nuamah I, Hough D.

Biol Psychiatry. 2011 Dec 15;70(12):1179-87. doi: 10.1016/j.biopsych.2011.06.021. Epub 2011 Aug 9.

PMID:
21831359

Supplemental Content

Support Center